泰林生物(300813.SZ):募投項目“細胞治療產業化裝備製造基地項目”尚未開始實施建設
格隆匯7月21日丨泰林生物(300813.SZ)發佈股票交易異常波動公吿稱,公司於2021年7月收到中國證券監督管理委員會下發的《關於同意浙江泰林生物技術股份有限公司向不特定對象發行可轉換公司債券註冊的批覆》(證監許可〔2021〕2258號),目前本次可轉債尚未發行,募投項目“細胞治療產業化裝備製造基地項目”尚未開始實施建設,存在一定的不確定性,敬請廣大投資者注意風險。公司將持續關注後續進展情況,並根據規定及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.